BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36566538)

  • 1. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
    Premnath N; Chung SS; Weinberg OK; Ikpefan R; Pandey M; Kaur G; Geethakumari PR; Afrough A; Awan FT; Anderson LD; Vusirikala M; Collins RH; Chen W; Agathocleous M; Madanat YF
    Leuk Res; 2023 Feb; 125():107001. PubMed ID: 36566538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
    Fujino T
    Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASXL1/2 mutations and myeloid malignancies.
    Medina EA; Delma CR; Yang FC
    J Hematol Oncol; 2022 Sep; 15(1):127. PubMed ID: 36068610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of ASXL1 in hematopoiesis and myeloid diseases.
    Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
    Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Ye B; Sheng Y; Zhang M; Hu Y; Huang H
    Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
    D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
    Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
    Pegliasco J; Hirsch P; Marzac C; Isnard F; Meniane JC; Deswarte C; Pellet P; Lemaitre C; Leroy G; Rabadan Moraes G; Guermouche H; Schmaltz-Panneau B; Pasquier F; Colas C; Benusiglio PR; Bera O; Bourhis JH; Brissot E; Caron O; Chraibi S; Cony-Makhoul P; Delaunay-Darivon C; Lapusan S; de Fontbrune FS; Fuseau P; Najman A; Vainchenker W; Delhommeau F; Micol JB; Plo I; Bellanné-Chantelot C
    Leukemia; 2022 Jan; 36(1):126-137. PubMed ID: 34172895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia.
    Liu J; Min S; Kim D; Park J; Park E; Pei S; Koh Y; Shin DY; Byun JM; Ko M; Yoon SS; Hong J
    Leukemia; 2023 Aug; 37(8):1638-1648. PubMed ID: 37393342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
    Hartmann L; Nadarajah N; Meggendorfer M; Höllein A; Vetro C; Kern W; Haferlach T; Haferlach C; Stengel A
    Leukemia; 2020 Mar; 34(3):811-820. PubMed ID: 31719678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
    Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia.
    Han YC; Park CY; Bhagat G; Zhang J; Wang Y; Fan JB; Liu M; Zou Y; Weissman IL; Gu H
    J Exp Med; 2010 Mar; 207(3):475-89. PubMed ID: 20212066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.